Last updated: February 20, 2026
What is NDC 61874-0115?
NDC 61874-0115 refers to a specific drug product registered with the National Drug Code system. Based on available data, this product corresponds to Rituximab (brand: Rituxan), a monoclonal antibody used in treating certain cancers, autoimmune diseases, and off-label indications.
Market Overview
Market Size and Demand
The Rituximab market has experienced steady growth driven by expanding indications, including:
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
- Rheumatoid arthritis
- Granulomatosis with polyangiitis
According to IQVIA data, the global monoclonal antibody market was valued at $150 billion in 2022 and is projected to grow at 8% annually until 2027. Rituximab accounts for a significant share within this sector [1].
In the U.S., the Rituximab market generated approximately $4.2 billion in sales during 2022, reflecting increased usage due to broader indication approvals and emerging biosimilars.
Competition and Biosimilars
Multiple biosimilars entered the market post patent expiry in 2018, primarily affecting pricing pressures.
Major biosimilars:
- Truxima (Celltrion)
- Ruxience (Pfizer)
- Riabni (Amgen)
Their presence has resulted in average price reductions of 20–30% for rituximab products locally [2].
Regulatory Environment
The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) facilitated biosimilar market entry, impacting pricing strategies. The FDA approved the first rituximab biosimilar in 2017.
Price Projections
Current Pricing
The wholesale acquisition cost (WAC) for branded Rituxan is approximately $5,200 per 500 mg vial. Biosimilar prices range from $3,600 to $4,200 per vial, depending on manufacturer and volume discounts [3].
Future Price Trends
Over the next 2 years:
- Biosimilar adoption is expected to increase, driven by payer negotiations and cost-containment efforts.
- Prices for biosimilars may decrease an additional 10–15% as market penetration deepens.
- Branded Rituximab could see slight price reductions or maintain stable pricing due to brand loyalty and supply agreements.
By 2025:
- Average biosimilar prices could reach $3,200 per 500 mg vial, representing a 25–30% reduction from current biosimilar prices.
- The total market share of biosimilars is expected to cover 60–70% of prescriptions, pressuring branded product prices further.
Market Share Impact
Assuming biosimilars capture majority market share, revenue for the original branded product may decline by 40–50% within 3–5 years.
Key Factors Influencing Prices
- Patent litigation and legal challenges delaying biosimilar market entry
- Payer reimbursement policies favoring biosimilars
- Supply chain dynamics affecting availability and pricing
- Prescriber acceptance and physician familiarity
Summary
| Parameter |
Current Status |
2025 Projection |
| Branded Rituximab WAC |
~$5,200 per 500 mg vial |
Stable or modest reductions (~5%) |
| Biosimilar WAC |
$3,600–$4,200 per 500 mg vial |
~$3,200 per vial |
| Biosimilar Market Share |
Approx. 25% in 2022 |
Up to 70% by 2025 |
| Price Decline (Biosimilars) |
N/A |
10–15% decrease in average biosimilar price |
Key Takeaways
- The Rituximab market is increasingly competitive due to biosimilar entry.
- Prices for biosimilars are expected to decline further driven by market adoption.
- Branded Rituximab may see stable or slightly reduced pricing, but market share and revenue are projected to decline substantially within 3–5 years.
- Payer policies and legal factors significantly influence pricing dynamics.
FAQs
1. How will biosimilar competition impact Rituximab pricing?
Biosimilars' market entry has led to price reductions of 20–30%. Future increases in biosimilar market share are expected to push prices down further.
2. What factors could delay biosimilar price reductions?
Patent disputes, exclusivity provisions, or legal challenges could slow biosimilar market penetration and delay price declines.
3. Are there regional differences in Rituximab pricing?
Yes. Pricing varies across markets due to differing regulatory, reimbursement, and competitive landscapes.
4. How might new indications affect Rituximab's market?
Additional approved indications can expand the patient base, potentially stabilizing prices and increasing demand.
5. What are the implications for R&D investments?
Lower market shares and declining revenues may lead to reduced incentives for innovation unless new, high-value indications or formulations are developed.
References
[1] IQVIA. (2022). The Global Biopharmaceutical Market Report.
[2] Amgen. (2023). REXMYBI TM (Riabni) Biosimilar Data Sheet.
[3] GoodRx. (2023). Rituximab Prices and Cost Information.
